Topic Overview

Detailed Notes on Mycobacterium kansasii Infection

---

Definition and General Description

Definition

Definition: A slow-growing, photochromogenic bacterium of Runyon Group I that causes both pulmonary and cutaneous infections.

Characteristics

• Most common in urban and industrial areas, particularly southern/central USA, southeast England, and northern France.

• Tap water serves as the primary reservoir, with no evidence of person-to-person transmission.

• Subtype 1, identified via PCR-RFLP of the hsp65 gene, is most commonly associated with clinical disease.

---

Epidemiology

• Incidence: A common NTM species isolated from clinical specimens, but cutaneous cases are rare.

• Demographics:
  Primarily affects middle-aged white men but can occur in adults of any age, sex, or race.

• Risk Factors:
  Associated with impaired immunity (e.g., HIV, malignancies, corticosteroid use) or occupational exposure to dust in miners, welders, and painters.

---

Pathophysiology

Predisposing Factors

• Chronic pulmonary conditions like COPD and cystic fibrosis.

• Immunosuppression due to HIV or medications.

Pathology

• Histologically, granulomatous inflammation resembling tuberculosis.

• Mixed inflammatory infiltrates with acid-fast bacilli; can present with necrosis, abscess formation, or cellulitis.

---

Clinical Features

Presentation

Cutaneous lesions:

• Papules

• Nodules

• Verrucous plaques

• Abscesses

• Cellulitis

• Sporotrichoid patterns reported

Systemic involvement:

• Disseminated disease seen in HIV or hematological malignancy cases, often life-threatening.

Complications

• Disseminated disease has a poor prognosis, with a 60% mortality rate.

---

Investigations

Culture and Staining

• Biopsy specimens stained for acid-fast bacilli.

• Cultured under conditions optimized for slow-growing mycobacteria.

PCR

• Useful in overcoming culture difficulties.

---

Management

First-Line Therapy

• Combination therapy with isoniazid, rifampicin, and ethambutol for 18 months.

• Sensitivity testing advised to optimize therapy.

Second-Line Options

• Addition of streptomycin or amikacin in severe cases for the first 3 months.

Third-Line Therapy

For resistant cases:

• Clarithromycin

• Levofloxacin

• Moxifloxacin

• Linezolid

---

Prognosis

Localized Disease

• Indolent progression with good response to treatment.

Disseminated Disease

• High mortality rate, underscoring the importance of early diagnosis and aggressive management.

---

These detailed notes capture the essential clinical, diagnostic, and therapeutic aspects of Mycobacterium kansasii infection.